Company news
Theravance Biopharma, Inc. (NASDAQ:TBPH) news
Theravance Biopharma, Inc. news releases on 6ix. Latest, Aug 10, 2026: Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides…
Press releases & updates
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
June 29, 2026
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 18, 2026
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
March 3, 2026
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
November 19, 2025
Theravance Biopharma to Participate in Upcoming Investor Conferences
November 18, 2025
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 9, 2025
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
October 28, 2025
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
October 26, 2025
Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy
October 15, 2025
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
October 13, 2025
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 1, 2025
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
August 24, 2025
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 11, 2025
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
July 27, 2025
Theravance Biopharma to Participate in an Upcoming Investor Conference
July 22, 2025
Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA
June 25, 2025
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
June 1, 2025
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
May 8, 2025
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 7, 2025
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
April 27, 2025
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
April 23, 2025
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting
April 6, 2025
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology
March 26, 2025
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
February 25, 2025
Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
February 11, 2025
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
December 16, 2024
Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
November 11, 2024
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
October 23, 2024
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
October 17, 2024
Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 4, 2024
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
July 21, 2024
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 12, 2024
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
April 28, 2024
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
April 9, 2024
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 25, 2024
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
February 13, 2024
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
January 4, 2024
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
December 20, 2023
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
December 17, 2023
Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System
November 15, 2023
Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 14, 2023
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
November 12, 2023
Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
November 6, 2023
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023
October 18, 2023
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders
August 27, 2023
Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
August 6, 2023
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023
July 23, 2023
Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy
May 8, 2023